$ACRV (NP) +53% on " $TRIL-like" financing, ~$100M EV Prior, had cash runway to Q4 2025 so didn't need $$ (funds must like data) ACR-368 yet another gem from $ARRY team (con= CoM patent expires 2030) If OncoSig works, opens up 30%+ addressable bladder & endometrial mkts
2
2
19
4K
4
Download Image
(will be interesting to see if drug #2 can widen therapeutic window for WEE1, increase potency while limiting on-target AEs- seems like quite the balancing act...)
@jfais20 I think they are presenting data in 1H 24.